Anti-amyloid antibody drugs in clinical testing for Alzheimer's disease

IDrugs

Volumn 12, Issue 9, 2009, Pages 566-575

  Bednar, Martin M ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Amyloid; Clinical trial; Immunotherapy; MAb

Indexed keywords

ACC 001; AD 01; AD 02; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; BAY 949172; BETABLOC; CAD 106; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE INHIBITOR; GANTENERUMAB; GSK 933776A; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LY 2062430; MABT 5102A; MONOCLONAL ANTIBODY; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PF 04360365; PF 4360365; R 1450; SEMAGACESTAT; SOLANEZUMAB; UNCLASSIFIED DRUG; V 950;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; CLINICAL TRIAL; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDEMA; HUMAN; IMMUNOTHERAPY; REVIEW; TREMOR; VASCULAR DISEASE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY;

EID: 69249127474     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Wippold FJ 2nd, Cairns N, Vo K, Holtzman DM, Morris JC: Neuropathology for the neuroradiologist: Plaques and tangles. AJNR Am J Neuroradiol (2008) 29(1):18-22.
2. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron (1991) 6(4):487-498.**Seminal paper to posit the amyloid hypothesis, drawing significantly from genetic studies to support this hypothesis.
3. Selkoe DJ: Alzheimer's disease: A central role for amyloid. J Neuropathol Exp Neurol (1994) 53(5):438-447.
4. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science (2002) 297(5580):353-356.
5. Hardy JA, Higgins GA: Alzheimer's disease: The amyloid cascade hypothesis. Science (1992) 256(5054):184-185.
6. 11C]PIB-PET study. Neurobiol Dis (2008) 32(3):412-419.
7. 141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA (1997) 94(5):2025- 2030.
8. Hardy J: The Alzheimer family of diseases: Many etiologies, one pathogenesis? Proc Natl Acad Sci USA (1997) 94(6):2095-2097.
9. Fernando MS, Ince PG: Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci (2004) 226(1-2):13-17.
10. 42 levels, incident dementia, and mortality in Down syndrome. Arch Neurol (2007) 64(7):1007-1013.
11. Zetterberg H, Blennow K: Biological CSF markers of Alzheimer's disease. Handb Clin Neurol (2008) 89:261-268.
12. 42, tau and phosphorylated tau, APOE ε4 allele and MCI type in progressive MCI. Neurobiol Aging (2007) 28(4):507-514.
13. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schroder J, Zinkowski RP, Bouwman FH, Schonknecht P, Schoonenboom NS, Andreasen N, Wallin A et al: Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 69(24):2205-2212.
14. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, Tochon-Danguy H, Chan G, Berlangieri SU, Jones G, Dickinson-Rowe KL et al: Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol (2008) 7(2):129-135.
15. 42 levels in the CSF.
16. Klunk WE, Mathis CA: The future of amyloid-β imaging: A tale of radionuclides and tracer proliferation. Curr Opin Neurol (2008) 21(6):683-687.
17. 42. Alzheimer's and Dementia (2008) 4(4 Suppl 1):Abs O3-02-02.
18. Nordberg A: Amyloid imaging in Alzheimer's disease. Curr Opin Neurol (2007) 20(4):398-402.
19. Blennow K, de Leon MJ, Zetterberg H: Alzheimer's disease. Lancet (2006) 368(9533):387-403.
20. Brody DL, Holtzman DM: Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 31:175-193.
21. Weiner HL, Frenkel D: Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol (2006) 6(5):404-416.
22. Desire L, Buee L, Lambeng N, Drouin D, Schweighoffer F: O3-05-02: EHT-0202: A neuroprotective and procognitive α-secretase stimulator targeted towards Alzheimer disease therapy. Alzheimer's and Dementia (2008) 4(4 Suppl 1):Abs O3-05-02.
23. Hirschler B: Mini antibodies: Biotech's next big thing? Thomson Reuters, London, UK (2008). www.reuters.com/article/healthNews/ idUSLC56746320080912?pageNumber=2&virtualBrandChannel=0&sp=true
24. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of β immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 64(9):1553-1562. * First paper to comprehensively describe the overall clinical outcome in patients with AD, who received from one to three administrations of AN-1792 (n = 300) or placebo (n = 72) and were followed for a minimum of 9 months after the last injection.
25. Winblad B: S2-04-06: Safety, tolerability and immunogenicity of the Aβ immunotherapeutic vaccine CAD106 in a first-in-man study in Alzheimer patients. Alzheimer;s and Dementia (2008) 4(4 Suppl 1):Abs S2-04-06.
26. Wyeth: Annual report 2001. Annual Report (2002): March 14.
27. Nitsch RM, Hock C: Targeting β-amyloid pathology in Alzheimer's disease with Aβ immunotherapy. Neurotherapeutics (2008) 5(3):415-420.
28. Panegyres PK: The functions of the amyloid precursor protein gene. Rev Neurosci (2001) 12(1):1-39.
29. Morgan D: Passive immunotherapies as an approach to disease modification in Alzheimer's disease. Satellite Symposium International Conference on Alzheimer's Disease, Chicago, IL, USA (2008).
30. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D: Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation (2006) 3:11.
31. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D: Deglycosylated anti-amyloid-β antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci (2006) 26(20):5340-5346.
32. Bednar MM, Zhao Q, Landen JW, Billing CB, Rohrbacher K, Kupiec JW: Safety and pharmacokinetics of the anti-amyloid monoclonal antibody PF-04360365 following a single infusion in patients with mild-to-moderate Alzheimer's Disease: Preliminary results. Alzheimer Dementia (2009) 5(4):P157.
33. Karlnoski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, Li Q, Gordon MN, Gottschall PE, Morgan D: Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J Neurosci (2009) 29(15):4964-4971.
34. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ: A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol (2009) 66(2):190-199.
35. Cacquevel M, Chéenne S, Lesne S, Carmeliet P, Buée L, Delacourte A, Bernaudin M, Buisson A, Vivien D: Tissue-type plasminogen activator promotes amyloid degradation. Society for Neuroscience Annual Meeting (2003) 33:Abs 876.11.
36. Szabo P, Esteban M, Monthe C, White L, Lent R, Relkin N, Weksler M: P2-393: Increasing the efficacy of immunotherapy for Alzheimer's disease (AD) with intravenous immunoglobulin (IVIG). Alzheimer's and Dementia (2006) 2(3 Suppl 1):Abs P2-393.
37. Gold R, Stangel M, Dalakas MC: Drug insight: The use of intravenous immunoglobulin in neurology Therapeutic considerations and practical issues. Nat Clin Pract Neurol (2007) 3(1):36-44.
38. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM et al: Exacerbation of cerebral amyloid angiopathyassociated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid β. J Neurosci (2005) 25(3):629-636.
39. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K et al: Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA (2003) 100(4):2023-2028.
40. Relkin NR: S1-02-02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin. Alzheimer's and Dementia (2008) 4(4 Suppl 1):Abs S1-02-02.
41. Lee VMY: Aβ immunization: Moving Aβ peptide from brain to blood. Proc Natl Acad Sci USA (2001) 98(16):8931-8932.
42. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98(15):8850-8855. ** Studying PDAPP (PDGF promoter expressing APP) transgenic mice, a rise in Aβ levels in the plasma of > 1000-fold was observed after the peripheral administration of a mAb targeting amyloid. This rise in Aβ was due, in part, to the peripheral effects of the mAb that altered the clearance of amyloid from the CNS.
43. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU, Ghebremedhin E, Thal DR: Cerebral small vessel disease-induced apolipoprotein E leakage is associated with Alzheimer disease and the accumulation of amyloid β-protein in perivascular astrocytes. J Neuropathol Exp Neurol (2008) 67(9):842-856.
44. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF: Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology (2007) 68(21):1809-1814.
45. DaSilva KA, Aubert I, McLaurin JA: Vaccine development for Alzheimer's disease. Curr Pharm Des (2006) 12(33):4283-4293.
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM et al: Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 14(8):837-842.
47. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 46(6):860-866.
48. 42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 372(9634):216-223. * A thought-provoking paper on the cognitive-histopathological relationship of a group of patients immunized with AN-1793 who were followed until death; results of the post-mortem autopsy were also analyzed.
49. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci (2002) 5(5):452-457. * Provides evidence that the reversal of memory deficits in transgenic mice may be affected by alterations in soluble amyloid rather than insoluble brain amyloid.
50. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC: β-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain (2007) 130(Pt 11):2837-2844.
51. Grundman M, Black R: O3-04-05: Clinical trials of bapineuzumab, a β-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimer's and Dementia (2008) 4(4 Suppl 1):Abs O3-04-05.
52. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE: Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol (2004) 61(3):378-384. * Human cognitive-neuropathological correlation from the Religious Orders Study, which provided evidence that tau may be the downstream mediator for the cognitive decline previously associated with the more proximal event of amyloid deposition.
53. International Conference on Alzheimer's Disease: Alzheimer's Association, Chicago, IL, USA (2008). www.alz.org/ICAD
54. Siemers ER, Friedrich S, Dean RA, Sethuraman G, DeMattos R, Jennings D, Tamagnan G, Marek K, Seibyl J: P4-346: Safety, tolerability and biomarker effects of an Aβ monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's and Dementia (2008) 4(4 Suppl 1):Abs P4-346.
55. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME: 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008):doi:10.1016/j.neurobiolaging.2007.12.021 * Despite a small patient population (n = 8), this study demonstrates an association of cognitive improvement/stabilization with changes in Aβ levels in the plasma and CSF during IVIg administration, with reversion to baseline during a 3-month withdrawal period that occurred between a 6-month and a 9-month IVIg dosing period.
56. Salloway S SR, Gregg K, Black R, Grundman M: Cognitive and functional outcomes from a phase II trial of bapineuzumab in mild to moderate Alzheimer's disease. American Academy of Neurology, Seattle, WA, USA (2009):Abs S32.002.
57. Mosconi L, Asamiak B, Tsakanikas D, Shah K, Kreisl W, Synan M,Morim S, Tsui W, De Leon M, Vallabhajousla S, Goldsmith S et al: Intravenous immunoglobulin increases brain glucose metabolism in Alzheimer disease. American Academy of Neurology, Seattle, WA, USA (2008):Abs S51.003.
58. Adamiak B, Monthe C, Bender H, Szabo P, Schiff R, Weksler ME, Relkin NR: O3-05-04: Intravenous immunoglobulin (IVIg) maintains cognition over 18 months in patients with Alzheimer's disease (AD). Alzheimer's and Dementia (2006) 2(3 Suppl 1):Abs O3-05-04.
59. A multicentre, randomised, double blind, placebo controlled, multiple ascending dose, safety, tolerability, and amyloidimaging positron emission tomography (PET) trial of AAB 001 (ELN115727) in patients with mild to moderate Alzheimer's disease (AD): Current Controlled Trials Ltd, London, UK (2009). controlled-trials.com/ISRCTN17517446
60. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M: Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 64(9):1563-1572.
61. Fox NC, DeCarli C, Black R, Grundman M: Effect of bapineuzumab on MRI measures of cerebral volume change in patients with Alzheimer's disease. American Academy of Neurology, Seattle, WA, USA (2009):Abs P03.098.
62. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JA: Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain. Brain (2008) 131(Pt 12):3299-3310.
63. Thal DR, Capetillo-Zarate E, Larionov S, Staufenbiel M, Zurbruegg S, Beckmann N: Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging (2008):doi:10.1016/j.neurobiolaging.2008.01.017.
64. 2O PET imaging, respectively, and were demonstrated to be inversely correlated in various (though not all) brain regions.
65. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H et al: RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 9(7):907-913. * Describes the interaction of Aβ with the receptor for advanced glycation endproducts (RAGE) at the BBB in transgenic mice, resulting in the transport of Aβ into the CNS and an associated proinflammatory response, thus outlining a possible target for modulating AD pathology.
66. Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, Hovanesian V, Hulette CM, Vitek MP, Cohen RA: Cerebral cortical arteriolar angiopathy, vascular β-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke (2008) 39(3): 814-821.
67. Farkas E, Luiten PG: Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol (2001) 64(6):575-611.
68. Wolozin B, Bednar MM: Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res (2006) 28(6): 630-636.
69. Sperling RA, Salloway S, Fox NC, Barackos J, Morris K, Francis G, Black RS, Grundman M: Risk factors and clinical course associated with vasogenic edema in a phase II trial of bapineuzumab. American Academy of Neurology, Seattle, WA, USA (2009):Abs S32.001
70. Siemers ER, Benson C, Gonzales C, Hansen R, Dean RA, Farlow MR, DeMattos R: O4-03-04: Safety assessments and biomarker changes following a monoclonal Aβ antibody given to subjects with Alzheimer's disease. Alzheimer's and Dementia (2006) 2(3 Suppl 1):Abs O4-03-04.
71. Wisniewski T, Konietzko U: Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol (2008) 7(9):805-811.
72. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K et al: Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 6(8): 916-919.
73. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 24(27):6144-6151.
74. Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ: Antibody-mediated phagocytosis of the amyloid β-peptide in microglia is differentially modulated by C1q. J Immunol (2001) 166(12):7496-7503.
75. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A et al: Alzheimer disease macrophages shuttle amyloid-β from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol (2009) 117(2):111-124.
76. Brody DL, Holtzman DM: Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 31:175-193.
77. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV: IgG-assisted age-dependent clearance of Alzheimer's amyloid β peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 25(50):11495-11503. * Describes neonatal Fc receptor-mediated transport of amyloid across the BBB; details of this process are relevant to understanding the equilibrium established for amyloid between central and peripheral compartments.
78. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 43(3):321-332.
79. Weller RO: CSF, interstitial fluid, cerebrovascular disease and Alzheimer's disease. The 4th International Congress of the International Society for Vascular Behavioral and Cognitive Disorders (VAS-COG), City of Singapore, Singapore (2009).
80. Black RS, Sperling R, Kirby L, Safirstein B, Motter R, Pallay A, Nichols A, Grundman M: A single ascending dose study of bapineuzumab, a humanized monoclonal antibody to Aβ, in AD. International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland/Springfield, IL, USA (2006).
81. Tsakanikas D, Shah K, Flores C, Assuras S, Relkin NR: P4-351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months. Alzheimer's and Dementia (2008) 4(4 Suppl 1):Abs P4-351.